Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
US6419957B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 24, 1999 |
| Grant date | Jul 16, 2002 |
| Priority date | — |
| Expiry date | Feb 24, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2059
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical agent, an optional polysaccharide or polyol, and high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a cross-linking agent with from about 0.1 g to about 40 g of cross-linking agent per 100 g of high amylose starch. In a preferred embodiment of the invention, the high amylose starch is modified with a functional group-attaching reagent that covalently bonds functional groups thereto.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.